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Abstract
Background: Distinguishing hydatidiform moles (HMs) from non-molar specimens and the subclassification of HM
are important because complete hydatidiform mole (CHM) is associated with an increased risk of gestational
trophoblastic neoplasia. However, diagnosis based solely on morphology has poor interobserver reproducibility.
Recent studies have demonstrated that the use of p57KIP2 immunostaining improves diagnostic accuracy for CHM.
Methods: We will conduct a systematic review of prospective and retrospective studies to evaluate the accuracy of
p57KIP2 immunostaining compared with molecular genotyping for the diagnosis of CHM. A high-sensitivity search
strategy will be employed in MEDLINE, EMBASE, LILACS, The Grey Literature Report, OpenGrey, OAIster, and
Cochrane CENTRAL. Two reviewers will independently screen all identified references for eligibility and extract data.
The methodological quality and bias of the included studies will be assessed according to the Quality Assessment
of Diagnostic Accuracy Studies (QUADAS-2) tool, and the overall quality of evidence will be assessed using the
Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. If a meta-analysis is
possible, pooled estimates of sensitivity, specificity, and positive and negative likelihood ratios will be calculated
using bivariate random-effects models. Statistical heterogeneity will be evaluated with I2 statistics and explored
through sensitivity analysis.
Discussion: There is considerable overlap between the histological features of molar and non-molar pregnancies
and between complete and partial HMs, which results in significant interobserver variability in the diagnosis of CHM
and its mimics. Therefore, molecular techniques are used to correctly diagnosis and treat CHM. However, these
molecular diagnostic methods are technically difficult to perform, relatively costly, and unavailable in most
pathology laboratories. According to our results, p57KIP2 immunostaining appears to be a practical and accurate
adjunct for the diagnosis of CHM and its mimics because this technique is relatively simple, reliable, cost-efficient,
and rapid. This systematic review will help to determine whether p57KIP2 immunostaining is an adequate alternative
diagnostic test for CHM.
Systematic review registration: PROSPERO CRD42015024181
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Background
Description of the condition
Hydatidiform mole (HM) is an abnormal gestational
condition characterized by significant hydropic enlarge-
ment and variable trophoblastic proliferation involving
part or all of the chorionic villi. Histopathological exam-
ination remains the basis for the diagnosis of HM; how-
ever, the diagnosis and classification of HM has become
increasingly difficult because HMs are now commonly
evacuated at an earlier stage and do not satisfy the well-
established classic morphological features [1]. Previous
studies have demonstrated that the diagnosis of HM
based on morphology alone is subject to interobserver
variability and therefore suboptimal diagnostic reprodu-
cibility [2, 3]. Differentiating a molar pregnancy from
non-molar specimens and the classification of HM as
complete hydatidiform mole (CHM), partial hydatidi-
form mole (PHM), early CHM (eCHM) or hydropic
abortion (HA) is important for both clinical practice and
investigational studies because the risk of persistent ges-
tational trophoblastic disease, including choriocarcin-
oma, is significantly higher after a pregnancy affected by
CHM (10–30 %) or PHM (0.5–5 %) compared with any
other pregnancy [2–4].
The p57KIP2 gene is paternally imprinted and maternally
expressed, and the presence of its protein product serves
as a surrogate marker for the nuclear maternal genome.
CHM is the only type of conceptus lacking a maternal
contribution, and p57KIP2 immunostaining is accordingly
absent, whereas it is present in CHM mimics [4].
Description of the index test
The index test will consist of p57KIP2 immunostaining.
P57KIP2 immunostaining is an in situ technique performed
on paraffin-embedded tissue. The results usually are easy to
interpret. P57 is a cyclin-dependent kinase inhibitor and
tumour suppressor gene located on chromosome 11p15.5.
The lack of p57KIP2 activity can lead to a loss of cell cycle
control, which results in the abnormal proliferation and
differentiation of trophoblasts in CHM. As expected, a lack
of the p57KIP2 protein product has been demonstrated in
immunohistochemistry (IHC)-based studies on CHMs, but
not in those on non-CHMs, which suggests that p57KIP2
IHC can be helpful for distinguishing CHM from its
mimics. The p57KIP2 gene (CDKN1C) is a strongly pater-
nally imprinted gene that is expressed only by the maternal
allele in most tissues and is involved in implantation.
P57KIP2 immunostaining is absent in CHM due to the lack
of a maternal genome [1].
Explanations for the negative expression of p57KIP2 in
discordant cases include misdiagnosed CHM, false-
negative results in a non-CHM patient, or a lack of
staining due to loss of antigenicity. False-positive
staining is attributed to the retention of maternal
chromosome 11, which is a phenomenon that is rarely
seen in CHM [1]. Immunostaining is assessed in the
nuclei of the villous mesenchymal cells (VMC) and
cytotrophoblasts. Positive immunostaining is considered
to exist when more than 10 % of the nuclei of the
cytotrophoblasts and VMC are stained. Immunostaining
of extravillous trophoblast cells, trophoblastic cells within
cell columns or islands, and interstitial trophoblasts at the
maternal-foetal junctional zones are observed as internal
positive controls. Syncytiotrophoblastic cells are used as
negative controls [1, 2, 4]. It was recently demonstrated
that p57KIP2 immunostaining can be helpful for refining
the diagnosis of some morphologically challenging cases
and for the detection of androgenetic cell lines in mosaic/
chimeric conceptions [1]. There are rare examples where
the morphology and immunophenotype (p57-negative) of
CHM occur in patients with familial recurrent HMs
associated with mutations in NLRP7 (NALP7) or
KHDC3L (C6orf221) [4].
Description of the standard test
Genotyping, which is accomplished through PCR
amplification of short tandem repeat loci, is particularly
valuable for the diagnosis of HM because it allows the
specific distinction of CHM, PHM, eCHM, and HA.
Through genotyping, CHM is diagnosed based on the
finding of purely androgenetic alleles. The vast majority
of CHMs are characterized by androgenetic diploidy
(two sets of paternal chromosome complements without
a maternal chromosome complement); however, a small
subset can exhibit androgenetic tetraploidy (genotyping
does not specifically distinguish examples of diploidy
from tetraploidy because peak heights do not indicate
the actual DNA content) [4]. Analysis of nuclear DNA
microsatellite polymorphisms is particularly well suited
for the diagnosis of MHC because it is capable of
determining the number and parental origin of alleles.
Molecular diagnostic methods such as genotyping are
limited because they are technically difficult, relatively
costly, and not universally available. In addition, ploidy
analysis does not differentiate between CHM and HA
because both are diploid. It has been reported that CHM
results from the fertilization of an enucleated egg by a
haploid sperm, followed by duplication of the sperm
genome (homozygous). However, in approximately
10–25 % of cases, the enucleated egg is fertilized by two
sperm cells (heterozygous). In some cases diagnosed
using microsatellite genotyping, androgenic CHM can
be misdiagnosed as biparental mole, containing maternal
alleles, due to possible contamination of the molar tissue
by maternal tissue that was inadvertently sent for
analysis. Analyses of genotyping results can be difficult
to interpret if abundant tissue of maternal origin is
present. Genotyping analysis plays an important role in
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the diagnosis of challenging cases with unusual p57KIP2
results [1, 4]. The goals of this systematic review are to
generate new quantitative evidence for clinicians and to
establish the accuracy of p57KIP2 IHC compared with
genotyping for the identification of CHM.
Methods
Design
The methodological approach for evidence searching and
synthesis described in this protocol will conform to the
Cochrane Collaboration’s methods for assessing diagnostic
test accuracy [5]. We will also follow the recommendations
of the Preferred Reporting Items for Systematic Review and
Meta-Analysis Protocols (PRISMA-P) included as an
additional file (Additional file 1) [6].
The study is registered at PROSPERO, the International
Prospective Register of Systematic Reviews, at the
University of York (CRD42015024181).
PIRO question
For analyses of the diagnostic accuracy of research
questions, the acronym PIRO is used, corresponding to P
(population), I (index test), R (reference standard), and O
(outcome).
The definitions of the components of the PIRO acro-
nym for this systematic review are as follows:
 Population: women of reproductive age (14–50 years)
 Index test: p57KIP2 immunohistochemistry
 Reference standard: genotyping
 Outcome: MHC idenification.
Search methods for identifying studies
Keywords and Medical Subject Headings related to HM,
p57KIP2 and molecular genotyping will be used alone or
in combination (together with synonyms and closely re-
lated words) to retrieve the relevant articles.
We will conduct searches in the Excerpta Medica
Database (EMBASE), Centro Latinoamericano y del Caribe
de Información en Ciencias de la Salud (LILACS), Medical
Literature Analysis and Retrieval System Online
(MEDLINE), Cochrane Central Register of Controlled
Trials (CENTRAL), and Web of Science. We will also
screen the reference lists of relevant studies and reviews for
additional articles and will search the grey literature
websites The Grey Literature Report, OpenGrey, and the
Open Archives Initiative (OAIster). If necessary (in the case
of unclear data, missing data or extractable data), we will at-
tempt to contact the corresponding authors of the included
studies for missing data and for clarification. The search
strategy developed for MEDLINE (see Additional file 2) will
be adapted for the other databases. There will be no
language or publication year restriction.
Eligibility criteria for the included studies
Any cross-sectional study, case series, case-control
study, cohort study, or clinical trial that evaluates the
accuracy of p57KIP2 immunostaining for the diagnosis of
CHM compared with genotyping will be included. Case
reports, narrative reviews, and expert opinions will be
excluded. Animal testing will be excluded.
Data collection
Two independent researchers will evaluate the titles and
abstracts arising from the combined search and will
independently extract all data from the retrieved articles
using a predefined data extraction sheet. A third author
will adjudicate any discrepancies.
In the case of duplicate publications or more than one
publication from a preliminary study, we will attempt to
maximize the use of the information by simultaneously
evaluating all of the available data, but we will not
include the same group of patients in the analysis more
than once.
The data will be extracted in the form of a data sheet
specifically developed for this analysis (Tables 1 and 2).
The following information will be extracted from each
study, with the possibility of adding further information
during the extraction process when appropriate:
 Study characteristics: title, author, country, design,
language of publication, year of publication, sample
size, and number of centres
 Population characteristics: total number of patients,
number of patients in groups for comparison, and
age of the patients
 Index test: type of test and diagnostic criteria
 Standard test: type of test and diagnostic criteria
 Outcomes: number of true positives, false positives,
true negatives, and false negatives, sensitivity and
specificity, negative predictive value (NPV) and positive
predictive value (PPV), and the positive likelihood ratio
(LR+) and negative likelihood ratio (LR−)
If there are any missing or insufficient data in the in-
cluded studies, we will contact the corresponding authors
of the studies via email to obtain additional information.
When more than one threshold is available, all data will
Table 1 Characteristics of the studies included












CHM complete hydatidiform mole, IHC immunohistochemistry,
Geno genotyping
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be recorded. A sensitivity analysis will be conducted to
assess the impact of including studies with 20 % or more
missing data.
Risk of bias assessment
We will assess the quality of the studies using the Quality
Assessment of Diagnostic Accuracy Studies (QUADAS-2)
tool [7]. If necessary, QUADAS-2 will be adapted to fit
different study designs included in accordance with our
research question. Grading of Recommendations Assess-
ment, Development, and Evaluation (GRADE) will be
used to rate the quality of the body of evidence retrieved
in the search [8].
Outcomes
The primary outcome will be the diagnostic accuracy of
p57KIP2 immunostaining for the diagnosis of CHM,
which will be described based on sensitivity and specifi-
city, negative and positive predictive values, and positive
and negative likelihood ratios wherever possible.
Statistical analysis
Where the data permit, we will compare the index test
against the reference test. For each study, we will extract
the number of true positives, true negatives, false
positives, and false negatives. When the raw data are
provided, contingency tables will be built to display the
results of the tests. The test results will be treated as
positive or negative for the cut-off values of the index
test. The sensitivity, specificity, positive predictive value,
false-positive rate, and positive likelihood ratio will be
calculated from the cut-off values of the index test.
Forest plots will be generated to illustrate sensitivity and
specificity and the 95 % confidence intervals (CI). The
diagnostic odds ratio (DOR) and the area under the
curve (AUC) of the summary ROC (summary receiver
operating characteristic (SROC)) will be calculated
because the summary statistics indicate the power of the
overall assessment for each of the two tests. A
hierarchical model, using the correlation between
sensitivity and specificity across the studies to provide a
summary of the model, will be employed to calculate the
pooled estimation using the R software 3.3.1 packages
metafor [9], mada [10], and HSROC [11]. The choice
between the bivariate random-effects model [12] and the
HSROC model from Rutter e Gatsonis [13] will be based
on the presence of different thresholds. Both approaches
can be used to compute estimates of the summary ROC
curve and the average operating point and allow us to
determine the extent of heterogeneity in the estimated
pooled measure. If heterogeneity is detected, we will
conduct a subgroup analysis and meta-regression to
evaluate the impact of the covariates in the pooled esti-
mation. The two models are mathematically equivalent
when no covariates are included in the model.
The magnitude of heterogeneity will be assessed using
Cochran’s Q statistic and Higgins I2 statistic, where an I2
greater than 50 % indicates the presence of significant
heterogeneity. The I2 statistic will be calculated according
to the following equation: I2 = 100 % × (Q − df)/Q, where Q
is the Cochran heterogeneity statistic [14]. If quantitative
synthesis is not appropriate, a descriptive analysis might be
undertaken.
We will perform a sensitivity analysis to examine the
effect of sample size and missing data on the results of
the review. If there are adequate studies (no less than
three studies), we will conduct a sensitivity analysis to
check the robustness of the conclusions and assess the
impact of the methodological quality.
The presence of publication bias will be assessed by
performing a regression of lnDOR and the effective sample
size (ESS) based on methods described by Deeks et al. [15].
Discussion
There is considerable overlap in histological features
between molar and non-molar pregnancies and between
CHMs and PHMs, which results in significant interob-
server variability in the diagnosis of HM and its mimics.
Therefore, correct diagnosis of these difficult cases may
require molecular techniques that examine the differences
in DNA content between CHM and PHM, including flow
or image cytometric DNA analysis, chromosome in situ
hybridization, polymerase chain reaction-based genotyping,
or HLA typing. However, these molecular diagnostic
methods are technically difficult to perform, relatively
costly, and unavailable in most pathology laboratories [1].
Banet et al. established that immunohistochemical
analysis of p57KIP2 expression is highly correlated with
genotyping results and demonstrated that CHM is
almost always p57-negative, with only rare examples
(0.5 %) displaying aberrant (positive) p57KIP2 expression,
which is attributable to retention of the maternal copy
of chromosome 11. CHMs are androgenetic conceptions
by definition, and the vast majority are monospermic
(85 %) [4].
The rare examples of aberrant p57KIP2 expression in
both CHM and PHM can be correctly classified using
genotyping. The findings of Banet et al. demonstrated
Table 2 Outcomes





TP true positive, FP false positive, TN true negative, FN false negative, S
sensitivity, E especificity, NPV negative predictive value, PPV positive predictive
value, LR likelihood ratio
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that p57KIP2 IHC is extremely reliable for the diagnosis
of CHM. Therefore, the algorithmic approach for the
diagnosis of HM proposed in this study advocates that
p57KIP2 results be used to triage cases for genotyping be-
cause this technique provides a highly reliable method
for accurately diagnosing CHM in routine practice using
a single immunohistochemical stain, with very little risk
of misclassification of CHM. Consequently, genotyping
for CHM is not necessary in routine practice and can be
reserved for problematic cases, such as when p57KIP2
immunostaining is suboptimal or unsatisfactory or when
there is a discrepancy between morphology and p57KIP2
results. One exception would be the case of recurrent
HM, which raises the possibility of familial biparental
HM. Patients with this disorder can have multiple/recur-
rent CHMs that are morphologically, immunophenotypi-
cally, and clinically similar to conventional CHMs;
specifically, they are p57-negative and appear to show a
similar risk of persistent gestational trophoblastic disease
but are characterized by biparental diploidy rather than
androgenetic diploidy [4].
Therefore, genotyping is useful in any patient with recur-
rent HMs to determine if they represent the familial form.
It is important to recognize that the biparental form exists
so that the genotyping results of biparental diploidy are not
used to reject a diagnosis of CHM when the morphology
and/or p57KIP2 results support a diagnosis of CHM [4].
Some studies [1, 4] have confirmed that p57KIP2
immunostaining is a practical and accurate adjunct for
the diagnosis of CHM and its mimics because this tech-
nique is a relatively simple, reliable, cost-efficient, and
rapid procedure. Therefore, the most ideal method for
correctly classifying all HMs and non-molar specimens
is a combined approach that includes the correlation of
morphological features, p57KIP2 IHC, and molecular
genotyping [4]. This combined approach is particularly
important when evaluating difficult and challenging
cases with discordant positive p57KIP2 staining, when
molecular techniques are still necessary [1]. The findings
of Banet et al. also confirmed that p57KIP2 IHC analysis
is useful for identifying androgenetic/biparental mosaic/
chimeric conceptions, which include uniformly andro-
genetic/biparental mosaic specimens without molar fea-
tures (probably early forms of placental mesenchymal
dysplasia, which is characterized by androgenetic/bipa-
rental mosaicism and a lack of trophoblastic hyperpla-
sia), androgenetic/biparental mosaic specimens with a
molar component (typically CHMs), and twin gestations
composed of CHM and non-molar specimen compo-
nents. Recognition of the discordant and divergent stain-
ing patterns in these specimens is key to correctly
interpreting these complex specimens and is necessary
for specific microdissection of the different components
to assure accurate molecular genotyping [4].
Therefore, we decided to perform this systematic re-
view and meta-analysis using the most definitive method
to assess the accuracy of p57KIP2 IHC compared with
molecular genotyping for the diagnosis of CHM.
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